Robinson Emma
School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, UK.
Brain Neurosci Adv. 2018 Nov 22;2:2398212818812629. doi: 10.1177/2398212818812629. eCollection 2018 Jan-Dec.
Psychopharmacology really developed as a discipline from the mid-20th century with the discovery of a number of new classes of psychoactive drugs which could modify behaviour. These drugs were discovered as a consequence of clinical observations of patients, often being treated for other conditions. These serendipitous discoveries were the start of an era of drug development which has led to the antidepressants, antipsychotics, anxiolytics and mood stabilisers used today. Subsequent research focused on understanding why these drugs were effective, and used this information to develop a second generation of drugs that were more selective for their therapeutic targets, and therefore had reduced side effects and improved safety and tolerability. After a period of decline in new discoveries and withdrawal of the majority of the major pharmaceutical companies from active development programmes in psychiatry, new avenues are emerging fuelling renewed interest in this area.
精神药理学真正作为一门学科是从20世纪中叶开始发展的,当时发现了许多能够改变行为的新型精神活性药物。这些药物是在对患者进行临床观察时发现的,这些患者通常是因其他疾病而接受治疗。这些意外发现开启了药物研发的时代,从而产生了如今使用的抗抑郁药、抗精神病药、抗焦虑药和情绪稳定剂。随后的研究集中在理解这些药物为何有效,并利用这些信息开发出第二代药物,这些药物对其治疗靶点更具选择性,因此副作用减少,安全性和耐受性得到改善。在新发现出现一段时间的衰退以及大多数大型制药公司退出精神病学的积极研发项目之后,新的途径正在出现,这激发了人们对该领域的新兴趣。